EGLE-THERAPEUTICS-SAS
17.7.2024 18:01:26 CEST | Business Wire | Press release
Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Promise of Interleukin-2 Therapy meeting taking place in Paris from September 4th to 7th, 2024.
The presentation, entitled “EGL-003, a novel IL-2 mutein to selectively expand and activate regulatory T cells and improve therapeutic efficacy in autoimmune disease”, will show evidence that EGL-003, a non-targeted Fc-fused IL-2 agonist mutein, selectively binds to regulatory T cells (Treg) and induces Treg IL-2 signaling.
The resulting increase of Treg frequencies was observed in vitro and in different mouse models. Accordingly, EGL-003 significantly improved clinical, macroscopic, and histological parameters in a DSS-induced colitis mouse model with expansion of tissue-resident Tregs.
EGL-003 is the first drug candidate being developed for treatment of autoimmune diseases in Egle’s pipeline and has advanced into IND-enabling studies.
Session Title: IL-2 and Treg cell therapies; Session Date and Time: Friday September 6th, 2024 2:00 PM - 3:30 PM; Location: Poster Section 4; Poster Board Number: 23 Published Abstract Number: 4079
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently in IND-enabling studies.
Find out more at www.egle-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717654160/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NEURA Robotics Introduces Neuron AI: The Brain of the Physical World14.10.2026 08:29:00 CEST | Press release
Beyond vision: Neuron AI brings 3D vision, touch, audio, robot state and language together with memory in one Perception-Language-Action (PLA) model, so robots can react to what they cannot seeOne model, every body: Trained on real-world robot data, simulation-amplified data and human demonstrations, Neuron AI runs across five NEURA robot embodiments and their grippers and handsFrom skill to fleet: Customers fine-tune Neuron AI for their own tasks and deploy skills across robot fleets via the platform Neuraverse, with Time-to-Skill as the central measure of progressAI built in Germany: Developed and trained in-house in Metzingen, GermanyLive at NVIDIA GTC Berlin: NEURA’s humanoid 4NE1 will complete an eleven-minute laundry task, fully autonomous from start to finish NEURA Robotics (“NEURA”) today introduced Neuron AI, its multimodal foundation model for Physical AI. Combining 3D vision, touch, audio, robot state and language with memory, Neuron AI enables robots to act on information b
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering14.10.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Acquisition brings together two highly complementary, science-backed skincare brands ZO Skin Health’s premium daily multi-step regimens complement Alastin’s regenerative skincare portfolio primarily focused on peri-procedure support Transaction expands Galderma’s Dermatological Skincare portfolio and offering in the attractive, fast-growing physician-dispensed skincare segment1 Galderma’s unique Integrated Dermatology Strategy, global scale and omni-channel execution capabilities expected to support ZO Skin Health’s next phase of growth Acquisition of 100% of ZO Skin Health for an enterprise value of 1.5 billion USD, expected to be Core EPS neutral in the first full year following closing Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone
Pretium Expands Middle East Presence with Abu Dhabi Office14.10.2026 06:02:00 CEST | Press release
Office will enable Pretium to engage more directly with institutional partners across the Middle East Pretium, a specialized investment firm with approximately $70 billion in assets under management1, today announced the opening of an office in Abu Dhabi. The office will operate within Abu Dhabi Global Market (“ADGM”), the international financial center of Abu Dhabi, providing proximity to some of the world’s leading institutional investors. The Abu Dhabi office marks an important step in the continued evolution of Pretium’s business. From its roots in U.S. residential real estate, Pretium has built a scaled investment platform spanning real estate equity and credit. A dedicated presence in Abu Dhabi will enhance the Firm’s connections to clients in the region as it continues to develop new investment solutions. “Abu Dhabi is home to some of the world’s most sophisticated and forward-looking institutional investors,” said Don Mullen, Founder and CEO of Pretium. “An on-the-ground presen
IFF to Release Third Quarter 2026 Results on November 3, 202613.10.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that it will release its third quarter 2026 earnings results following the market close on Tuesday, November 3, 2026. The management team will host a live webcast on Wednesday, November 4, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, and health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire
Industry Leaders Formally Launch SCMP OCP Workstream for Open, Secure AI Infrastructure Management and Control13.10.2026 19:15:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, and AMI, a Lattice company, today announced SCMP (Secure Control and Management Plane), a new Open Compute Project workstream. Announced during a joint keynote at the 2026 OCP Global Summit, SCMP is an open, vendor-neutral architecture for secure control, boot, and management of data center infrastructure. It gives data center operators more confidence that complex AI systems will work as expected across vendors and platforms, with less integration risk and more freedom of choice. SCMP defines how a control authority establishes and maintains trust from silicon root of trust through rack and pod, building on existing OCP initiatives and industry standards. “As AI infrastructure scales toward autonomous operation, the management and control plane becomes the foundation of trust. That foundation should be open and verifiable, and SCMP gives the industry a common architecture to achieve it, from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom